PharmacoEconomics

1997 - 2020

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla ().

Access Statistics for this journal.
Track citations for all items by RSS feed
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 38, issue 2, 2020

Talkin’ About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices pp. 125-134

Brendan Shaw and Jorge Mestre-Ferrandiz

One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit pp. 135-141

Christopher McCabe, Mike Paulden, Isaac Awotwe, Andrew Sutton and Peter Hall

A Review of Health Economic Studies Comparing Traditional and Massively Parallel Sequencing Diagnostic Pathways for Suspected Genetic Disorders pp. 143-158

Patrick Fahr, James Buchanan and Sarah Wordsworth

Measurement Properties of Commonly Used Generic Preference-Based Measures in East and South-East Asia: A Systematic Review pp. 159-170

Xinyu Qian, Rachel Lee-Yin Tan, Ling-Hsiang Chuang and Nan Luo

Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment pp. 171-179

David D. Kim, Gregory F. Guzauskas, Caroline S. Bennette, Anirban Basu, David L. Veenstra, Scott D. Ramsey and Josh J. Carlson

Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada pp. 181-192

Feng Tian, Sherilyn K. D. Houle, Mhd. Wasem Alsabbagh and William W. L. Wong

How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness pp. 193-204

Ben Kearns, John Stevens, Shijie Ren and Alan Brennan

Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models pp. 205-216

Sabine E. Grimm, Xavier Pouwels, Bram L. T. Ramaekers, Ben Wijnen, Saskia Knies, Janneke Grutters and Manuela A. Joore

Transferability of Economic Evaluations of Treatments for Advanced Melanoma pp. 217-231

Claire Gorry, Laura McCullagh and Michael Barry

Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis pp. 233-242

T. Joseph Mattingly, Julia F. Slejko, Eberechukwu Onukwugha, Eleanor M. Perfetto, Shyamasundaran Kottilil and C. Daniel Mullins

Volume 38, issue 1, 2020

The New and Non-Transparent Cancer Drugs Fund pp. 1-4

Eifiona M. Wood and Dyfrig A. Hughes

Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians pp. 5-24

Alisa Likhitsup and Neehar D. Parikh

Economic Burden of Anxiety Disorders: A Systematic Review and Meta-Analysis pp. 25-37

Alexander Konnopka and Hannah König

A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA pp. 39-56

Elizabeth Wehler, Natalie Boytsov, Claudia Nicolay, Oscar Herrera-Restrepo and Stacey Kowal

Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study pp. 57-68

Dean A. Regier, David L. Veenstra, Anirban Basu and Josh J. Carlson

Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan pp. 69-84

Luis Hernandez, Hiroyo Kuwabara, Anshul Shah, Kaoru Yamabe, Heather Burnett, Kyle Fahrbach, Maria Koufopoulou and Ryuichi Iwakiri

Bayesian Hierarchical Models for Meta-Analysis of Quality-of-Life Outcomes: An Application in Multimorbidity pp. 85-95

Susanne Schmitz, Tatjana T. Makovski, Roisin Adams, Marjan Akker, Saverio Stranges and Maurice P. Zeegers

Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes pp. 97-108

Caitlin Smare, Khalid Lakhdari, Justin Doan, John Posnett and Sukhvinder Johal

The Value of Shorter Initial Opioid Prescriptions: A Simulation Evaluation pp. 109-119

Margrét V. Bjarnadóttir, David R. Anderson, Kislaya Prasad, Ritu Agarwal and D. Alan Nelson

Comment on: ‘NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence’ pp. 121-122

Livio Garattini and Nicholas Freemantle

Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA pp. 123-123

Elizabeth Wehler, Natalie Boytsov, Claudia Nicolay, Oscar Herrera-Restrepo and Stacey Kowal

Volume 37, issue 12, 2019

Could or Should We Use MCDA in the French HTA Process? pp. 1417-1419

Salah Ghabri, Jean-Michel Josselin and Benoît Maux

Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma: A Systematic Review pp. 1421-1449

Shuangshuang Fu, Chi-Fang Wu, Michael Wang and David R. Lairson

Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design pp. 1451-1468

Daniel M. Sugrue, Thomas Ward, Sukhvir Rai, Phil McEwan and Heleen G. M. Haalen

The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments pp. 1469-1483

Fernando Antonanzas, Carmelo Juárez-Castelló, Reyes Lorente and Roberto Rodríguez-Ibeas

Performance of the UKPDS Outcomes Model 2 for Predicting Death and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus from a German Population-Based Cohort pp. 1485-1494

Michael Laxy, Verena Maria Schöning, Christoph Kurz, Rolf Holle, Annette Peters, Christa Meisinger, Wolfgang Rathmann, Kristin Mühlenbruch and Katharina Kähm

Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II—An Updated Analysis of SEER-Medicare Data pp. 1495-1507

Ya-Chen Tina Shih, Ying Xu, Chun-Ru Chien, Bumyang Kim, Yu Shen, Liang Li and Daniel M. Geynisman

Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn’s Disease pp. 1509-1523

Heather Catt, Keith Bodger, Jamie J. Kirkham and Dyfrig A. Hughes

A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis pp. 1525-1536

Sandjar Djalalov, Jaclyn Beca, Emmanuel M. Ewara and Jeffrey S. Hoch

Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies pp. 1537-1551

Venediktos Kapetanakis, Thibaud Prawitz, Michael Schlichting, K. Jack Ishak, Hemant Phatak, Mairead Kearney, John W. Stevens, Agnes Benedict and Murtuza Bharmal

Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review pp. 1553-1553

Dongzhe Hong, Lei Si, Minghuan Jiang, Hui Shao, Wai-kit Ming, Yingnan Zhao, Yan Li and Lizheng Shi

Volume 37, issue 11, 2019

Improving Transparency in Decision Models: Current Issues and Potential Solutions pp. 1303-1304

Paul Tappenden and J. Jaime Caro

The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood pp. 1305-1312

Seamus Kent, Frauke Becker, Talitha Feenstra, An Tran-Duy, Iryna Schlackow, Michelle Tew, Ping Zhang, Wen Ye, Shi Lizheng, William Herman, Phil McEwan, Wendelin Schramm, Alastair Gray, Jose Leal, Mark Lamotte, Michael Willis, Andrew J Palmer and Philip Clarke

Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project pp. 1313-1320

Jeroen P. Jansen, Devin Incerti and Mark T. Linthicum

Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States pp. 1321-1327

Josh J. Carlson, Surrey M. Walton, Anirban Basu, Richard H. Chapman, Jonathan D. Campbell, R. Brett McQueen, Steven D. Pearson, Daniel R. Touchette, David Veenstra, Melanie D. Whittington and Daniel A. Ollendorf

A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling pp. 1329-1339

Fernando Alarid-Escudero, Eline M. Krijkamp, Petros Pechlivanoglou, Hawre Jalal, Szu-Yu Zoe Kao, Alan Yang and Eva A. Enns

Cooking Up a Transparent Model Following a DICE Recipe pp. 1341-1347

Jörgen Möller

Transparency in Health Economic Modeling: Options, Issues and Potential Solutions pp. 1349-1354

Eric Q. Wu, Zheng-Yi Zhou, Jipan Xie, Cinzia Metallo and Praveen Thokala

Transparency in Decision Modelling: What, Why, Who and How? pp. 1355-1369

Christopher Sampson, Renée Arnold, Stirling Bryan, Philip Clarke, Sean Ekins, Anthony Hatswell, Neil Hawkins, Sue Langham, Deborah Marshall, Mohsen Sadatsafavi, Will Sullivan, Edward C. F. Wilson and Tim Wrightson

Can You Repeat That? Exploring the Definition of a Successful Model Replication in Health Economics pp. 1371-1381

Emma McManus, David Turner and Tracey Sach

NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence pp. 1383-1390

Ash Bullement, Matthew Taylor, Sam Thomas McMordie, Errol Waters and Anthony James Hatswell

TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility pp. 1391-1408

Nasuh C. Büyükkaramikli, Maureen P. M. H. Rutten- van Mölken, Johan L. Severens and Maiwenn Al

Publication of Decision Model Source Code: Attitudes of Health Economics Authors pp. 1409-1410

Joanna Emerson, Rachel Bacon, Alma Kent, Peter J. Neumann and Joshua T. Cohen

Correction to: Publication of Decision Model Source Code: Attitudes of Health Economics Authors pp. 1411-1411

Joanna Emerson, Rachel Bacon, Alma Kent, Peter J. Neumann and Joshua T. Cohen

Volume 37, issue 10, 2019

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 1195-1207

Sabine E. Grimm, Debra Fayter, Bram L. T. Ramaekers, Svenja Petersohn, Rob Riemsma, Nigel Armstrong, Xavier Pouwels, Willem Witlox, Caro Noake, Gillian Worthy, Jos Kleijnen and Manuela A. Joore

Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 1209-1217

Matthew Walton, Sahar Sharif, Mark Simmonds, Lindsay Claxton and Robert Hodgson

Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review pp. 1219-1239

Xiao Zang, Emanuel Krebs, Linwei Wang, Brandon D. L. Marshall, Reuben Granich, Bruce R. Schackman, Julio S. G. Montaner and Bohdan Nosyk

Cost Effectiveness of Advanced Pharmacy Services Provided in the Community and Primary Care Settings: A Systematic Review pp. 1241-1260

Dalia M. Dawoud, Alexander Haines, David Wonderling, Joanna Ashe, Jennifer Hill, Mihir Varia, Philip Dyer and Julian Bion

Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations pp. 1261-1276

Jesse Elliott, Sasha Katwyk, Bláthnaid McCoy, Tammy Clifford, Beth K. Potter, Becky Skidmore, George A. Wells and Doug Coyle

Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand pp. 1277-1286

Khachen Kongpakwattana, Zanfina Ademi, Thanaputt Chaiyasothi, Surakit Nathisuwan, Ella Zomer, Danny Liew and Nathorn Chaiyakunapruk

Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013 pp. 1287-1300

Elizabeth D. Brouwer, Anirban Basu and Kai Yeung

Comment on: ‘The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study’ pp. 1301-1302

Livio Garattini and Anna Padula

Volume 37, issue 9, 2019

Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 1073-1080

Shijie Ren, Hazel Squires, Emma Hock, Eva Kaltenthaler, Andrew Rawdin and Constantine Alifrangis

The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal pp. 1081-1091

Edward Cox, Ros Wade, Mathilde Peron, Kristina Charlotte Dietz, Alison Eastwood, Stephen Palmer and Susan Griffin

Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions pp. 1093-1127

Marina Treskova, Stefan M. Scholz and Alexander Kuhlmann

Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations pp. 1129-1138

Mario J. N. M. Ouwens, Pralay Mukhopadhyay, Yiduo Zhang, Min Huang, Nicholas Latimer and Andrew Briggs

Mapping the PedsQL™ onto the CHU9D: An Assessment of External Validity in a Large Community-Based Sample pp. 1139-1153

Christine Mpundu-Kaambwa, Gang Chen, Elisabeth Huynh, Remo Russo and Julie Ratcliffe

Severity-Adjusted Probability of Being Cost Effective pp. 1155-1163

Matthijs M. Versteegh, Isaac Corro Ramos, Nasuh C. Buyukkaramikli, Amir Ansaripour, Vivian T. Reckers-Droog and Werner B. F. Brouwer

Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe pp. 1165-1176

Dominik Golicki, Michał Jakubczyk, Katarzyna Graczyk and Maciej Niewada

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States pp. 1177-1193

Thomas E. Delea, Xinke Zhang, Jordan Amdahl, Diana Boyko, Franziska Dirnberger, Marco Campioni and Ze Cong

Volume 37, issue 8, 2019

Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma pp. 975-984

Frederick W. Thielen, Nasuh C. Büyükkaramikli, Rob Riemsma, Debra Fayter, Nigel Armstrong, Ching-Yun Wei, Vanesa Huertas Carrera, Kate Misso, Gill Worthy, Jos Kleijnen and Isaac Corro Ramos

Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal pp. 985-993

Becky Pennington, Shije Ren, Samantha Barton, Mariana Bacelar and Steven J. Edwards

Cost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature Review pp. 995-1010

Nikolaos Maniadakis and Evgenia Konstantakopoulou

Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review pp. 1011-1027

Stuart J. Wright, William G. Newman and Katherine Payne

The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective pp. 1029-1039

Simon Frey, Tom Stargardt, Udo Schneider and Jonas Schreyögg

A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator’s Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck pp. 1041-1047

Kim Cocks, Marta Contente, Sarah Simpson, Michael DeRosa, Fiona C. Taylor and James W. Shaw

Is Reclassification of the Oral Contraceptive Pill from Prescription to Pharmacist-Only Cost Effective? Application of an Economic Evaluation Approach to Regulatory Decisions pp. 1049-1064

Mutsa Gumbie, Bonny Parkinson, Henry Cutler, Natalie Gauld and Virginia Mumford

Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States” pp. 1065-1067

Katrine Wallace, Sandra Goble, Jeff Isaacson, Lara Maloney, Terri Cameron and Josh Bedel

Correction to: Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO) pp. 1069-1069

Hui Shao, Vivian Fonseca, Charles Stoecker, Shuqian Liu and Lizheng Shi

Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia pp. 1071-1071

Mark Bounthavong, Javed Butler, Chantal M. Dolan, Jeffrey D. Dunn, Kathryn A. Fisher, Nina Oestreicher, Bertram Pitt, Paul J. Hauptman and David L. Veenstra

Volume 37, issue 7, 2019

The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis pp. 871-877

Eric Jutkowitz, Fernando Alarid-Escudero, Karen M. Kuntz and Hawre Jalal

Autologous Chondrocyte Implantation with Chondrosphere for Treating Articular Cartilage Defects in the Knee: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 879-886

Xavier Armoiry, Ewen Cummins, Martin Connock, Andrew Metcalfe, Pamela Royle, Rhona Johnston, Jeremy Rodrigues, Norman Waugh and Hema Mistry

Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 887-894

Bram L. T. Ramaekers, Rob Riemsma, Sabine Grimm, Debra Fayter, Sohan Deshpande, Nigel Armstrong, Willem Witlox, Xavier Pouwels, Steven Duffy, Gill Worthy, Jos Kleijnen and Manuela A. Joore

A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective pp. 895-919

Steve Ryder, Kathleen Fox, Pratik Rane, Nigel Armstrong, Ching-Yun Wei, Sohan Deshpande, Lisa Stirk, Yi Qian and Jos Kleijnen

Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation pp. 921-929

Hui Shao, Shuang Yang, Vivian Fonseca, Charles Stoecker and Lizheng Shi

Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients pp. 931-941

Michelle Tew, Philip Clarke, Karin Thursky and Kim Dalziel

Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease pp. 943-952

Yawen Jiang and Weiyi Ni

The Cancer Drugs Fund in Practice and Under the New Framework pp. 953-962

Celia Sabry-Grant, Kinga Malottki and Alexander Diamantopoulos

Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States” pp. 963-964

R. Brett McQueen, Melanie D. Whittington, Rick H. Chapman, Varun M. Kumar and Jonathan D. Campbell

Response to ‘Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”’ pp. 965-967

Holly Guy, Lydia Walder and Mark Fisher

Correction to: Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities? pp. 969-969

Paul Mark Mitchell, Sridhar Venkatapuram, Jeff Richardson, Angelo Iezzi and Joanna Coast

Correction to: Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial pp. 971-971

Baptiste Leurent, Manuel Gomes, Rita Faria, Stephen Morris, Richard Grieve and James R. Carpenter

Correction to: Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health Utilities pp. 973-973

Edna Keeney, Dalia Dawoud and Sofia Dias

Volume 37, issue 6, 2019

Cost-Effectiveness Analysis in the Context of US Commercial Health Insurance pp. 743-744

Bryan Dowd and John A. Nyman

Combining the Power of Artificial Intelligence with the Richness of Healthcare Claims Data: Opportunities and Challenges pp. 745-752

David Thesmar, David Sraer, Lisa Pinheiro, Nick Dadson, Razvan Veliche and Paul Greenberg

Fulvestrant for Untreated Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 753-762

Joanna Picot, Neelam Kalita, Wendy Gaisford, Petra Harris, Oluchukwu Onyimadu and Keith Cooper

Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 763-775

Sarah Davis, Rachid Rafia, Christopher Carroll, Jean Hamilton and Munira Essat

Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review pp. 777-818

Dongzhe Hong, Lei Si, Minghuan Jiang, Hui Shao, Wai-kit Ming, Yingnan Zhao, Yan Li and Lizheng Shi

Estimation of Cost for Endoscopic Screening for Esophageal Cancer in a High-Risk Population in Rural China: Results from a Population-Level Randomized Controlled Trial pp. 819-827

Fuxiao Li, Xiang Li, Chuanhai Guo, Ruiping Xu, Fenglei Li, Yaqi Pan, Mengfei Liu, Zhen Liu, Chao Shi, Hui Wang, Minmin Wang, Hongrui Tian, Fangfang Liu, Ying Liu, Jingjing Li, Hong Cai, Li Yang, Zhonghu He and Yang Ke

A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis pp. 829-843

Devin Incerti, Jeffrey R. Curtis, Jason Shafrin, Darius Lakdawalla and Jeroen P. Jansen

Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden pp. 845-865

Santiago Zuluaga-Sanchez, Megan Teynor, Christopher Knight, Robin Thompson, Thomas Lundqvist, Mats Ekelund, Annabelle Forsmark, Adrian D. Vickers and Andrew Lloyd

Correction to: The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study pp. 867-867

José Leal, Stefania Manetti and James Buchanan

Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 869-869

Hema Mistry, Chidozie Nduka, Martin Connock, Jill Colquitt, Theodoros Mantopoulos, Emma Loveman, Renata Walewska and James Mason

Volume 37, issue 5, 2019

Beneluxa: What are the Prospects for Collective Bargaining on Pharmaceutical Prices Given Diverse Health Technology Assessment Processes? pp. 627-630

James F. O’Mahony

An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis pp. 631-643

Matthew Franklin, James Lomas, Simon Walker and Tracey Young

Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal pp. 645-654

Lindsay Claxton, Joanne O’Connor, Nerys Woolacott, Kath Wright and Robert Hodgson

Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 655-667

Sabine E. Grimm, Nigel Armstrong, Bram L. T. Ramaekers, Xavier Pouwels, Shona Lang, Svenja Petersohn, Rob Riemsma, Gillian Worthy, Lisa Stirk, Janine Ross, Jos Kleijnen and Manuela A. Joore

Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review pp. 669-688

Natalia Ruiz-Negrón, Jyothi Menon, Jordan B. King, Junjie Ma and Brandon K. Bellows

Doxycycline Added to Prednisolone in Outpatient-Treated Acute Exacerbations of COPD: A Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial pp. 689-699

Aureliano Paolo Finch, Patricia van Velzen, Gerben ter Riet, Peter J. Sterk, Jan M. Prins and Judith E. Bosmans

Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States pp. 701-714

Holly Guy, Vicki Laskier, Mark Fisher, W. Richey Neuman, Iwona Bucior, Steven Deitelzweig and Alexander T. Cohen

EQ-5D-5L Valuation for the Malaysian Population pp. 715-725

Asrul Akmal Shafie, Annushiah Vasan Thakumar, Ching Jou Lim, Nan Luo, Kim Rand-Hendriksen and Faridah Aryani Md Yusof

Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology pp. 727-737

Istvan M. Majer, Jean-Gabriel Castaigne, Stephen Palmer, Lucy DeCosta and Marco Campioni

Correction to: Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal pp. 739-739

Lindsay Claxton, Joanne O’Connor, Nerys Woolacott, Kath Wright and Robert Hodgson

Correction to: Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study pp. 741-741

Matthew Franklin, Sarah Davis, Michelle Horspool, Wei Sun Kua and Steven Julious

Volume 37, issue 4, 2019

Advances in Methods and Novel Applications for Measuring Family Spillover Effects of Illness pp. 447-450

Lisa A. Prosser and Eve Wittenberg

The Inclusion of Spillover Effects in Economic Evaluations: Not an Optional Extra pp. 451-456

Werner Brouwer

Expanding the Scope of Costs and Benefits for Economic Evaluations in Health: Some Words of Caution pp. 457-460

Christopher McCabe

Quantifying Family Spillover Effects in Economic Evaluations: Measurement and Valuation of Informal Care Time pp. 461-473

Scott D. Grosse, Jamison Pike, Rieza Soelaeman and J. Mick Tilford

Spillover Effects on Caregivers’ and Family Members’ Utility: A Systematic Review of the Literature pp. 475-499

Eve Wittenberg, Lyndon P. James and Lisa A. Prosser

Using Discrete-Choice Experiment Methods to Estimate the Value of Informal Care: The Case of Children with Intellectual Disability pp. 501-511

Sheena Arora, Stephen Goodall, Rosalie Viney and Stewart Einfeld

Parental Health Spillover in Cost-Effectiveness Analysis: Evidence from Self-Harming Adolescents in England pp. 513-530

Sandy Tubeuf, Eirini-Christina Saloniki and David Cottrell

The Monetary Value of Informal Care: Obtaining Pure Time Valuations Using a Discrete Choice Experiment pp. 531-540

Renske J. Hoefman, Job van Exel and Werner Brouwer

Parent Preferences for Health Outcomes Associated with Autism Spectrum Disorders pp. 541-551

Tara A. Lavelle, Milton C. Weinstein, Joseph P. Newhouse, Kerim Munir, Karen A. Kuhlthau and Lisa A. Prosser

Economic Spillover Effects of Intensive Unpaid Caregiving pp. 553-562

Josephine C. Jacobs, Courtney Van Houtven, Terri Tanielian and Rajeev Ramchand

Dementia Family Caregivers’ Willingness to Pay for an In-home Program to Reduce Behavioral Symptoms and Caregiver Stress pp. 563-572

Eric Jutkowitz, Danny Scerpella, Laura T. Pizzi, Katherine Marx, Quincy Samus, Catherine Verrier Piersol and Laura N. Gitlin

Close-Person Spill-Overs in End-of-Life Care: Using Hierarchical Mapping to Identify Whose Outcomes to Include in Economic Evaluations pp. 573-583

Alastair Canaway, Hareth Al-Janabi, Philip Kinghorn, Cara Bailey and Joanna Coast

An Examination of Downstream Effects of Bereavement on Healthcare Utilization for Surviving Spouses in a National Sample of Older Adults pp. 585-596

Katherine A. Ornstein, Melissa M. Garrido, Albert L. Siu, Evan Bollens-Lund, Omari-Khalid Rahman and Amy S. Kelley

Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer’s Disease Interventions pp. 597-608

Pei-Jung Lin, Brittany D’Cruz, Ashley A. Leech, Peter J. Neumann, Myrlene Sanon Aigbogun, Dorothee Oberdhan and Tara A. Lavelle

Measuring Health Spillover Effects in Caregivers of Children with Autism Spectrum Disorder: A Comparison of the EQ-5D-3L and SF-6D pp. 609-620

Clare C. Brown, J. Mick Tilford, Nalin Payakachat, D. Keith Williams, Karen A. Kuhlthau, Jeffrey M. Pyne, Renske J. Hoefman and Werner Brouwer

The Inclusion of Spillover Effects in Economic Evaluation: A Public Health Economics Perspective pp. 621-623

Rhiannon Tudor Edwards

Correction to: Parental Health Spillover in Cost‑Effectiveness Analysis: Evidence from Self‑Harming Adolescents in England pp. 625-625

Sandy Tubeuf, Eirini-Christina Saloniki and David Cottrell

Volume 37, issue 3, 2019

Determining Value in Health Technology Assessment: Stay the Course or Tack Away? pp. 293-299

J. Jaime Caro, John Brazier, Jonathan Karnon, Peter Kolominsky-Rabas, Alistair J. McGuire, Erik Nord and Michael Schlander

Economic Burden of Renal Cell Carcinoma—Part I: An Updated Review pp. 301-331

Chun-Ru Chien, Daniel M. Geynisman, Bumyang Kim, Ying Xu and Ya-Chen Tina Shih

Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 333-343

Paul Tappenden, Emma Simpson, Jean Hamilton, Daniel Pollard, Mark Clowes, Eva Kaltenthaler, David Meiklejohn and Nick Morley

Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 345-357

Tosin Lambe, Rui Duarte, James Mahon, Sarah Nevitt, Janette Greenhalgh, Angela Boland, Sophie Beale, Eleanor Kotas, Joanne McEntee and Ian Pomeroy

Evaluating Cost-Effectiveness Models for Pharmacologic Interventions in Adults with Heart Failure: A Systematic Literature Review pp. 359-389

Gian Luca Di Tanna, Anna Bychenkova, Frank O’Neill, Heidi S. Wirtz, Paul Miller, Briain Ó Hartaigh and Gary Globe

Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States pp. 391-405

Holly Guy, Lydia Walder and Mark Fisher

Measuring Public Preferences for Health Outcomes and Expenditures in a Context of Healthcare Resource Re-Allocation pp. 407-417

Nicolas Krucien, Nathalie Pelletier-Fleury and Amiram Gafni

Opioid Use is Associated with Higher Severity-Adjusted Episode Costs in Patients with Conservatively Managed Degenerative Joint Disease of the Back and Neck pp. 419-433

Brent A. Metfessel, Michelle D. Mentel, Amy Phanel, Mary Ann Dimartino, Mureen Allen and Samuel Ho

Cost Effectiveness of Inhaled Mannitol (Bronchitol®) in Patients with Cystic Fibrosis pp. 435-446

Emma Warren, Kristen Morgan, Toby J. Toward, Matthias Schwenkglenks and Joanna Leadbetter

Volume 37, issue 2, 2019

Future Costs in Cost-Effectiveness Analyses: Past, Present, Future pp. 119-130

Linda M. Vries, Pieter H. M. Baal and Werner Brouwer

Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal pp. 131-139

Ros Wade, Alessandro Grosso, Emily South, Claire Rothery, Pedro Saramago, Laetitia Schmitt, Kath Wright and Stephen Palmer

Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 141-153

Nasuh C. Büyükkaramikli, Saskia Groot, Rob Riemsma, Debra Fayter, Nigel Armstrong, Piet Portegijs, Steven Duffy, Jos Kleijnen and Maiwenn J. Al

The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence pp. 155-167

Richard Perry, George Braileanu, Thomas Palmer and Paul Stevens

Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review pp. 169-200

Edward T. Chiyaka, Nghiem Van T., Lu Zhang, Abhishek Deshpande, Patricia Dolan Mullen and Phuc Le

Discrete Choice Experiments in Health Economics: Past, Present and Future pp. 201-226

Vikas Soekhai, Esther W. Bekker-Grob, Alan R. Ellis and Caroline Vass

Does a Patient-Directed Financial Incentive Affect Patient Choices About Controller Medicines for Asthma? A Discrete Choice Experiment and Financial Impact Analysis pp. 227-238

Tracey-Lea Laba, Helen K. Reddel, Nicholas J. Zwar, Guy B. Marks, Elizabeth Roughead, Anthony Flynn, Michele Goldman, Aine Heaney, Kirsty Lembke and Stephen Jan

Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States pp. 239-253

Eytan Stein, Jipan Xie, Emilie Duchesneau, Subrata Bhattacharyya, Umakanth Vudumula, Briana Ndife, Gaetano Bonifacio, Annie Guerin, Nanxin Li and George Joseph

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data pp. 255-266

Andrea Marcellusi, Raffaella Viti, Loreta A. Kondili, Stefano Rosato, Stefano Vella and Francesco Saverio Mennini

Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand pp. 267-278

Bunchai Chongmelaxme, Pochamana Phisalprapa, Ratree Sawangjit, Piyameth Dilokthornsakul and Nathorn Chaiyakunapruk

Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding pp. 279-289

Thananan Rattanachotphanit, Chulaporn Limwattananon, Onanong Waleekhachonloet, Phumtham Limwattananon and Kittisak Sawanyawisuth

Correction to: Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand pp. 291-291

Bunchai Chongmelaxme, Pochamana Phisalprapa, Ratree Manthaisong, Piyameth Dilokthornsakul and Nathorn Chaiyakunapruk

Volume 37, issue 1, 2019

Trusting the Results of Model-Based Economic Analyses: Is there a Pragmatic Validation Solution? pp. 1-6

Salah Ghabri, Matt Stevenson, Jörgen Möller and J. Jaime Caro

Ibrutinib for Treating Waldenström’s Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 7-18

Paul Tappenden, Christopher Carroll, John Stevens, Emma Simpson, Praveen Thokala, Ruth Wong, Josh Wright and Rebecca Auer

Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 19-27

Daniel Gallacher, Xavier Armoiry, Peter Auguste, Rachel Court, Theodoros Mantopoulos, Jacoby Patterson, Maria Santis, Joanne Cresswell and Hema Mistry

One Method, Many Methodological Choices: A Structured Review of Discrete-Choice Experiments for Health State Valuation pp. 29-43

Brendan Mulhern, Richard Norman, Deborah J. Street and Rosalie Viney

Systematic Literature Review of the Economic Burden of Celiac Disease pp. 45-61

Elizabeth S. Mearns, Aliki Taylor, Talia Boulanger, Kelly J. Craig, Michele Gerber, Daniel A. Leffler, Jennifer Drahos, David S. Sanders and Benjamin Lebwohl

Exploring Different Strategies of Assessing the Economic Impact of Multiple Diabetes-Associated Complications and Their Interactions: A Large Claims-Based Study in Germany pp. 63-74

Katharina Kähm, Michael Laxy, Udo Schneider and Rolf Holle

The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals pp. 75-84

Becky Pennington, Monica Hernandez-Alava, Stephen Pudney and Allan Wailoo

Health State Utilities for Acute Myeloid Leukaemia: A Time Trade-off Study pp. 85-92

Namita Joshi, Marja Hensen, Sachin Patel, Weiwei Xu, Kathy Lasch and Elly Stolk

Estimating Informal Caregiving Time from Patient EQ-5D Data: The Informal CARE Effect (iCARE) Tool pp. 93-103

Maria Gheorghe, Renske J. Hoefman, Matthijs M. Versteegh and Job Exel

Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer pp. 105-116

Min Huang, M. Catherine Pietanza, Ayman Samkari, James Pellissier, Thomas Burke, Sheenu Chandwani, Fansen Kong and A. Simon Pickard

Correction to: The Future of Precision Medicine: Potential Impacts for Health Technology Assessment pp. 117-117

James Love-Koh, Alison Peel, Juan Carlos Rejon-Parrilla, Kate Ennis, Rosemary Lovett, Andrea Manca, Anastasia Chalkidou, Hannah Wood and Matthew Taylor